Oncobiologics Q3 EPS Increased by Brookline Capital Markets

Oncobiologics, Inc. (NASDAQ:OTLK) – Analysts at Brookline Capital Markets raised their Q3 2026 earnings per share (EPS) estimates for Oncobiologics in a research note issued to investors on Monday, March 30th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.13) for the quarter, up from their prior estimate of ($0.17). The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. Brookline Capital Markets also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.55) EPS and FY2027 earnings at ($0.14) EPS.

Oncobiologics (NASDAQ:OTLK) last issued its quarterly earnings results on Tuesday, February 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The company had revenue of ($1.21) million for the quarter, compared to analyst estimates of $3.14 million.

A number of other research firms also recently weighed in on OTLK. Ascendiant Capital Markets dropped their target price on Oncobiologics from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Chardan Capital restated a “neutral” rating on shares of Oncobiologics in a report on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a research note on Friday, March 27th. HC Wainwright reaffirmed a “neutral” rating on shares of Oncobiologics in a report on Wednesday, February 18th. Finally, Wall Street Zen downgraded Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $4.50.

Oncobiologics Price Performance

Shares of OTLK stock traded up $0.01 during trading hours on Tuesday, reaching $0.21. 5,836,548 shares of the company were exchanged, compared to its average volume of 4,908,575. Oncobiologics has a fifty-two week low of $0.16 and a fifty-two week high of $3.39. The stock’s fifty day moving average is $0.38 and its two-hundred day moving average is $1.01. The company has a market cap of $17.60 million, a price-to-earnings ratio of -0.08 and a beta of 0.18.

Institutional Investors Weigh In On Oncobiologics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.